Efficacy and safety of GSK3196165 versus placebo and tofacitinib in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to conventional synthetic/biologic DMARDs.

Brief description of study

This study will compare otilimab with tofacitinib or placebo in addition to your current csDMARD treatment(s), which you will continue to receive. Otilimab is given as a subcutaneous (SC) injection (under the skin). Tofacitinib is taken as a capsule by mouth. Placebo will be available as capsules and SC injections. The capsule (tofacitinib or placebo) should be taken in the morning and in the evening, at about the same time every day with or without food.

Clinical Study Identifier: s19-00142
ClinicalTrials.gov Identifier: NCT03970837
Principal Investigator: David H. Goddard.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.